Devices and processes for distribution of genetic material to mammalian limb
View Patent ↗A process is described for the delivery of a therapeutic polynucleotide to limb muscle tissue suffering from or potentially suffering from ischemia. The polynucleotide is inserted into a mammalian limb vessel such as an artery. Delivery efficiency and distribution is enhanced by combining injection of a solution containing the polynucleotide with the use of an externally applied cuff.
1. An in vivo process for improving blood flow in a limb muscle tissue of a mammal comprising:
a) inserting an injector into a blood vessel in the limb of the mammal;
b) applying a device external to mammalian skin for compressing vessels in an area underneath the device thereby occluding fluid flow into and out of the limb;
c) injecting a solution containing polynucleotides encoding a peptide or protein selected from the group consisting of an angiogenic factor and an arteriogenesis factor into the lumen of said blood vessel distal to the occlusion wherein the solution is retained within the limb, thereby increasing the volume of fluid in the limb and delivering the polynucleotides to skeletal muscle cells in the limb; and,
d) expressing the polynucleotides in the skeletal muscle cells thereby improving said blood flow in said tissue.
2. The process of claim 1 wherein the polynucleotides are selected from the group consisting of viral vectors and non-viral vectors.
3. The process of claim 1 wherein the externally applied device consists of a tourniquet placed over the skin.
4. The process of claim 1 wherein the externally applied device consists of a cuff placed over the skin.
5. The process of claim 4 wherein the externally applied device consists of a sphygmomanometer cuff placed over the skin.
6. The process of claim 1 wherein improving blood flow consists of stimulating new blood vessel formation.
7. The process of claim 1 wherein the angiogenic factor consists of vascular endothelial growth factor.
8. The process of claim 1 wherein the angiogenic factor consists of fibroblast growth factor.
9. The process of claim 8 wherein the fibroblast growth factor is selected from the list consisting of: FGF-1, FGF-1b, FGF-1c, FGF-2, FGF-2b, FGF-2c, FGF-3, FGF-3b, FGF-3c, FGF-4, FGF-5, FGF-7, FGF-9, acidic FGF and basic FGF.
10. The process of claim 1 , wherein expression of the polynucleotides stimulates angiogenesis in the muscle tissue.
11. The process of claim 1 wherein improving blood flow consists of improving collateral blood flow.
12. The process of claim 11 wherein improving collateral blood flow consists of stimulating collateral blood vessel formation.
13. The process of claim 1 wherein the muscle tissue is affected by a vascular occlusion.
14. The process of claim 1 wherein the muscle tissue is at risk of being affected by a vascular occlusion.
15. The process of claim 1 wherein the muscle tissue is suffering from ischemia.
16. The process of claim 1 wherein the muscle tissue is at risk of suffering from ischemia.
17. The process of claim 1 wherein the mammal has peripheral vascular disease.
18. The process of claim 1 wherein the mammal has peripheral arterial occlusive disease.
19. The process of claim 1 wherein the mammal has peripheral-deficient vascular disease.
20. The process of claim 17 wherein the mammal suffers from claudication or intermittent claudication.
21. The process of claim 20 wherein delivery of the polynucleotides results in decreased pain associated with a peripheral circulatory disorder.
22. The process of claim 1 wherein the peptide or protein is secreted from the muscle cell.
23. The process of claim 1 wherein the peptide or protein stimulates vascular cell growth.
24. The process of claim 1 wherein delivery of the polynucleotides stimulates vascular cell migration.
25. The process of claim 1 wherein delivery of the polynucleotides stimulates vascular cell proliferation.